TrialHaematologica2012

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

François Guilhot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.